# Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

> **NCT00859898** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1093 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Metformin XR
- **DRUG:** Metformin XR
- **DRUG:** dapagliflozin matching Placebo
- **DRUG:** metformin HCl Modified Release matching Placebo

## Key facts

- **NCT ID:** NCT00859898
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 1093 (ACTUAL)
- **Last updated:** 2016-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859898, "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00859898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*